Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.57 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | GRK6 | P43250 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366389 | 1.00 | NR1H2 (0.68) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL5678433 | 0.90 | NR1H2 (0.64) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL10476810 | 0.89 | NR1H2 (0.67) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL11176066 | 0.89 | NR1H2 (0.67) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL17280037 | 0.88 | NR1H2 (0.50) | NR1H2NR1H3ADORA2ANPC1TP53 | |
| SCHEMBL10476823 | 0.86 | NR1H2 (0.59) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL11171315 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3ADORA2AADORA1NPC1 | |
| SCHEMBL10476791 | 0.84 | NR1H2 (0.73) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 | |
| SCHEMBL11171303 | 0.83 | NR1H2 (0.60) | NR1H2NR1H3ADORA2ANPC1TP53 | |
| SCHEMBL11172345 | 0.82 | NR1H2 (0.63) | NR1H2NR1H3ADORA2AADORA1DCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4379155-A | 3,5-Disubstituted-1H-1,2,4-triazole derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-04-05 | — | — | US | claimed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20100292231-A1 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers | AJAMI ALFRED M | 2010-11-18 | — | — | US | disclosed |
| US-20100292231-A1 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers | AJAMI ALFRED M | 2010-11-18 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-RE38962-E1 | Diphenyl-triazole derivatives and their use as anti-gestative immuno-suppressant and anti-tumoral agents | GEANGE LTD. (IE) | 2006-01-31 | — | — | US | disclosed |
| US-6333343-B1 | HETEROCYCLIC, AROMATIC COMPOUNDS AND ANTITUMOR AGENTS | GEANGE LTD. (IE) | 2001-12-25 | — | — | US | disclosed |
| EP-0986544-A1 | DIPHENYL-TRIAZOLE DERIVATIVES AND THEIR USE AS ANTI-GESTATIVE, IMMUNO-SUPPRESSANT AND ANTI-TUMORAL AGENTS | Geange Ltd. (IE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998055463-A1 | DIPHENYL-TRIAZOLE DERIVATIVES AND THEIR USE AS ANTI-GESTATIVE, IMMUNO-SUPPRESSANT AND ANTI-TUMORAL AGENTS | GEANGE LTD. (IE) | 1998-12-10 | — | — | WO | disclosed |
| US-4888350-A | ANTIFERTILITY AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1989-12-19 | — | — | US | disclosed |
| US-4459302-A | CONTRACEPTIVES | GRUPPO LEPETIT, S.P.A. (IT) | 1984-07-10 | — | — | US | disclosed |
| US-4379155-A | 3,5-Disubstituted-1H-1,2,4-triazole derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-04-05 | — | — | US | disclosed |
| US-4370336-A | OXYTOCICS | GRUPPO LEPETIT S.P.A. (IT) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | NR1H2 705/4885NR1H3 764/4885ADORA2A 3884/4885 |
| US-20100292231-A1 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers | FLT3, CSF3R, CSF1R | NR1H2 997/4885NR1H3 1191/4885ADORA2A 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.